Cargando…
The clinical outcomes and biomarker features of severe sepsis/septic shock with severe neutropenia: a retrospective cohort study
BACKGROUND: Severe sepsis/septic shock with severe neutropenia often leads to poor prognosis. However, it is unknown if severe neutropenia is associated with different clinical outcomes and biomarker features in severe sepsis/septic patients. METHODS: This retrospective cohort study enrolled 141 sev...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039791/ https://www.ncbi.nlm.nih.gov/pubmed/33850805 http://dx.doi.org/10.21037/tp-20-230 |
_version_ | 1783677669333794816 |
---|---|
author | Yin, Fan Xi, Yue-Ling Wang, Ying Li, Bi-Ru Qian, Juan Ren, Hong Zhang, Jian Tang, Hong-Zhi Ning, Bo-Tao |
author_facet | Yin, Fan Xi, Yue-Ling Wang, Ying Li, Bi-Ru Qian, Juan Ren, Hong Zhang, Jian Tang, Hong-Zhi Ning, Bo-Tao |
author_sort | Yin, Fan |
collection | PubMed |
description | BACKGROUND: Severe sepsis/septic shock with severe neutropenia often leads to poor prognosis. However, it is unknown if severe neutropenia is associated with different clinical outcomes and biomarker features in severe sepsis/septic patients. METHODS: This retrospective cohort study enrolled 141 severe sepsis/septic shock patients admitted to intensive care unit of Shanghai Children’s Medical Center between January 2015 and November 2019. Patients were followed up for the development of ventilation support, the use of vasoactive drugs, continuous renal replacement therapy (CRRT) procedure, and mortality. Biomarkers that reflect the level of inflammation in severe sepsis/septic shock patients with neutropenia were compared to that in patients without neutropenia. RESULTS: Of 141 patients enrolled, 54 patients suffered from severe sepsis/septic shock with severe neutropenia. In patients with severe sepsis/septic shock, severe neutropenia as a complication was an independent risk factor for the use of vasoactive drugs (RR 9.796; 95% CI: 3.774, 25.429; P<0.001), but not for ventilation support (RR 0.157; 95% CI: 0.06, 0.414; P<0.001), CRRT procedure (RR 1.032; 95% CI: 0.359, 2.969; P=0.953) or 28-day mortality (RR 1.405; 95% CI: 0.533, 3.708; P=0.492). Severe sepsis/septic patients with severe neutropenia had a higher plasma level of the following biomarkers: c-reaction protein (CRP) (180.5 vs. 121 mg/mL, P<0.001), procalcitonin (PCT) (12.15 vs. 2.7 ng/mL; P=0.005), interleukin (IL)-6 (316.83 vs. 55.77 pg/mL, P<0.001), IL-10 (39.165 vs. 10.09 pg/mL, P<0.001), interferon (IFN)-γ (6.155 vs. 3.71 pg/mL, P=0.016), and the percentage of regulatory T cells (Tregs) (2.7% vs. 2.09%, P=0.003). Based on the receiver operating characteristic curves, IL-10 exhibited high specificity (79.4%) in evaluating the prognosis of septic patients with neutropenia. CONCLUSIONS: In patients with severe sepsis/septic shock, being complicated with severe neutropenia is associated with higher proportion of using vasoactive drugs, and those patients tend to have higher plasma levels of IL-6, IL-10, IFN-γ and percentage of Treg. |
format | Online Article Text |
id | pubmed-8039791 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-80397912021-04-12 The clinical outcomes and biomarker features of severe sepsis/septic shock with severe neutropenia: a retrospective cohort study Yin, Fan Xi, Yue-Ling Wang, Ying Li, Bi-Ru Qian, Juan Ren, Hong Zhang, Jian Tang, Hong-Zhi Ning, Bo-Tao Transl Pediatr Original Article BACKGROUND: Severe sepsis/septic shock with severe neutropenia often leads to poor prognosis. However, it is unknown if severe neutropenia is associated with different clinical outcomes and biomarker features in severe sepsis/septic patients. METHODS: This retrospective cohort study enrolled 141 severe sepsis/septic shock patients admitted to intensive care unit of Shanghai Children’s Medical Center between January 2015 and November 2019. Patients were followed up for the development of ventilation support, the use of vasoactive drugs, continuous renal replacement therapy (CRRT) procedure, and mortality. Biomarkers that reflect the level of inflammation in severe sepsis/septic shock patients with neutropenia were compared to that in patients without neutropenia. RESULTS: Of 141 patients enrolled, 54 patients suffered from severe sepsis/septic shock with severe neutropenia. In patients with severe sepsis/septic shock, severe neutropenia as a complication was an independent risk factor for the use of vasoactive drugs (RR 9.796; 95% CI: 3.774, 25.429; P<0.001), but not for ventilation support (RR 0.157; 95% CI: 0.06, 0.414; P<0.001), CRRT procedure (RR 1.032; 95% CI: 0.359, 2.969; P=0.953) or 28-day mortality (RR 1.405; 95% CI: 0.533, 3.708; P=0.492). Severe sepsis/septic patients with severe neutropenia had a higher plasma level of the following biomarkers: c-reaction protein (CRP) (180.5 vs. 121 mg/mL, P<0.001), procalcitonin (PCT) (12.15 vs. 2.7 ng/mL; P=0.005), interleukin (IL)-6 (316.83 vs. 55.77 pg/mL, P<0.001), IL-10 (39.165 vs. 10.09 pg/mL, P<0.001), interferon (IFN)-γ (6.155 vs. 3.71 pg/mL, P=0.016), and the percentage of regulatory T cells (Tregs) (2.7% vs. 2.09%, P=0.003). Based on the receiver operating characteristic curves, IL-10 exhibited high specificity (79.4%) in evaluating the prognosis of septic patients with neutropenia. CONCLUSIONS: In patients with severe sepsis/septic shock, being complicated with severe neutropenia is associated with higher proportion of using vasoactive drugs, and those patients tend to have higher plasma levels of IL-6, IL-10, IFN-γ and percentage of Treg. AME Publishing Company 2021-03 /pmc/articles/PMC8039791/ /pubmed/33850805 http://dx.doi.org/10.21037/tp-20-230 Text en 2021 Translational Pediatrics. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Yin, Fan Xi, Yue-Ling Wang, Ying Li, Bi-Ru Qian, Juan Ren, Hong Zhang, Jian Tang, Hong-Zhi Ning, Bo-Tao The clinical outcomes and biomarker features of severe sepsis/septic shock with severe neutropenia: a retrospective cohort study |
title | The clinical outcomes and biomarker features of severe sepsis/septic shock with severe neutropenia: a retrospective cohort study |
title_full | The clinical outcomes and biomarker features of severe sepsis/septic shock with severe neutropenia: a retrospective cohort study |
title_fullStr | The clinical outcomes and biomarker features of severe sepsis/septic shock with severe neutropenia: a retrospective cohort study |
title_full_unstemmed | The clinical outcomes and biomarker features of severe sepsis/septic shock with severe neutropenia: a retrospective cohort study |
title_short | The clinical outcomes and biomarker features of severe sepsis/septic shock with severe neutropenia: a retrospective cohort study |
title_sort | clinical outcomes and biomarker features of severe sepsis/septic shock with severe neutropenia: a retrospective cohort study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039791/ https://www.ncbi.nlm.nih.gov/pubmed/33850805 http://dx.doi.org/10.21037/tp-20-230 |
work_keys_str_mv | AT yinfan theclinicaloutcomesandbiomarkerfeaturesofseveresepsissepticshockwithsevereneutropeniaaretrospectivecohortstudy AT xiyueling theclinicaloutcomesandbiomarkerfeaturesofseveresepsissepticshockwithsevereneutropeniaaretrospectivecohortstudy AT wangying theclinicaloutcomesandbiomarkerfeaturesofseveresepsissepticshockwithsevereneutropeniaaretrospectivecohortstudy AT libiru theclinicaloutcomesandbiomarkerfeaturesofseveresepsissepticshockwithsevereneutropeniaaretrospectivecohortstudy AT qianjuan theclinicaloutcomesandbiomarkerfeaturesofseveresepsissepticshockwithsevereneutropeniaaretrospectivecohortstudy AT renhong theclinicaloutcomesandbiomarkerfeaturesofseveresepsissepticshockwithsevereneutropeniaaretrospectivecohortstudy AT zhangjian theclinicaloutcomesandbiomarkerfeaturesofseveresepsissepticshockwithsevereneutropeniaaretrospectivecohortstudy AT tanghongzhi theclinicaloutcomesandbiomarkerfeaturesofseveresepsissepticshockwithsevereneutropeniaaretrospectivecohortstudy AT ningbotao theclinicaloutcomesandbiomarkerfeaturesofseveresepsissepticshockwithsevereneutropeniaaretrospectivecohortstudy AT yinfan clinicaloutcomesandbiomarkerfeaturesofseveresepsissepticshockwithsevereneutropeniaaretrospectivecohortstudy AT xiyueling clinicaloutcomesandbiomarkerfeaturesofseveresepsissepticshockwithsevereneutropeniaaretrospectivecohortstudy AT wangying clinicaloutcomesandbiomarkerfeaturesofseveresepsissepticshockwithsevereneutropeniaaretrospectivecohortstudy AT libiru clinicaloutcomesandbiomarkerfeaturesofseveresepsissepticshockwithsevereneutropeniaaretrospectivecohortstudy AT qianjuan clinicaloutcomesandbiomarkerfeaturesofseveresepsissepticshockwithsevereneutropeniaaretrospectivecohortstudy AT renhong clinicaloutcomesandbiomarkerfeaturesofseveresepsissepticshockwithsevereneutropeniaaretrospectivecohortstudy AT zhangjian clinicaloutcomesandbiomarkerfeaturesofseveresepsissepticshockwithsevereneutropeniaaretrospectivecohortstudy AT tanghongzhi clinicaloutcomesandbiomarkerfeaturesofseveresepsissepticshockwithsevereneutropeniaaretrospectivecohortstudy AT ningbotao clinicaloutcomesandbiomarkerfeaturesofseveresepsissepticshockwithsevereneutropeniaaretrospectivecohortstudy |